MacroGenics Inc
NASDAQ:MGNX
MacroGenics Inc
NASDAQ:MGNX
Price:
15.55 USD
5.21%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
MGNX
stock under the Base Case scenario is
5.48
USD.
Compared to the current market price of 15.55 USD,
MacroGenics Inc
is
Overvalued by 65%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MGNX
Relative Value
Base Case
5.48
USD
Overvaluation 65%
Valuation Multiples
Multiples Across Competitors
MGNX Competitors Multiples
MacroGenics Inc Competitors
MacroGenics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
MacroGenics Inc
NASDAQ:MGNX
|
965.2m USD | 16.4 | -106.6 | -4.6 | -4.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.4 | 44.9 | 61.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
